Welcome to the international HTA database

Showing [16733 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2016	National Institute for Health and Care Excellence (NICE)	Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal). NICE technology appraisal guidance 382
2016	NIHR Health Technology Assessment programme	DiPALS: Diaphragm Pacing in patients with Amyotrophic Lateral Sclerosis - a randomised controlled trial
2016	NIHR Health Services and Delivery Research programme	Demand management for planned care: a realist synthesis
2016	National Institute for Health and Care Excellence (NICE)	Nivolumab for treating advanced (unresectable or metastatic) melanoma. NICE technology appraisal guidance 384
2016	NIHR Health Technology Assessment programme	A programme of studies including assessment of diagnostic accuracy of school hearing screening tests and a cost-effectiveness model of school entry hearing screening programmes
2016	National Institute for Health and Care Excellence (NICE)	Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia. NICE technology appraisal guidance 385
2016	Belgian Health Care Knowledge Centre (KCE)	Economic evaluation of novel direct acting antiviral (DAA) treatment strategies for chronic hepatitis C
2016	Canadian Agency for Drugs and Technologies in Health (CADTH)	Cognitive processing therapy for post-traumatic stress disorder: a systematic review and meta-analysis
2016	National Institute for Health and Care Excellence (NICE)	Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis. NICE technology appraisal guidance 386
2016	NIHR Health Technology Assessment programme	A randomised placebo-controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study
2016	Canadian Agency for Drugs and Technologies in Health (CADTH)	DNA mismatch repair deficiency tumour testing for patients with colorectal cancer: a health technology assessment
2016	National Institute for Health and Care Excellence (NICE)	Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. NICE technology appraisal guidance 387
2016	NIHR Health Technology Assessment programme	A multicentre, randomised controlled trial comparing the clinical effectiveness and cost-effectiveness of early nutritional support via the parenteral versus the enteral route in critically ill patients (CALORIES)
2016	Agency for Healthcare Research and Quality (AHRQ)	Disparities within serious mental illness
2016	Canadian Agency for Drugs and Technologies in Health (CADTH)	Capnography for monitoring end-tidal CO2 in hospital and pre-hospital settings: a health technology assessment
2016	National Institute for Health and Care Excellence (NICE)	Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction. NICE technology appraisal guidance 388
2016	NIHR Health Technology Assessment programme	A systematic review of the clinical effectiveness and cost-effectiveness of pharmacological and psychological interventions for the management of obsessive-compulsive disorder in children/adolescents and adults
2016	Health Quality Ontario (HQO)	Composite tissue transplant of hand or arm: a health technology assessment
2016	Canadian Agency for Drugs and Technologies in Health (CADTH)	Monitoring for atrial fibrillation in discharged stroke and transient ischemic attack patients: a clinical and cost-effectiveness analysis and review of patient preferences
2016	National Institute for Health and Care Excellence (NICE)	Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer. NICE technology appraisal guidance 389
2016	NIHR Health Technology Assessment programme	Comparison Of iNfliximab and ciclosporin in Steroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT)
2016	Agenzia nazionale per i servizi sanitari regionali (Agenas)	Sutureless aortic valve replacement (SuAVR) for aortic stenosis
2016	National Institute for Health and Care Excellence (NICE)	Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes. NICE technology appraisal guidance 390
2016	NIHR Health Technology Assessment programme	PROMISE: first-trimester progesterone therapy in women with a history of unexplained recurrent miscarriages - a randomised, double-blind, placebo-controlled, international multicentre trial and economic evaluation
2016	NIHR Health Technology Assessment programme	The feasibility of determining the effectiveness and cost-effectiveness of medication organisation devices compared with usual care for older people in a community setting: systematic review, stakeholder focus groups and feasibility randomised controlled trial
2016	Agenzia nazionale per i servizi sanitari regionali (Agenas)	Implantable Left Ventricular Assist Device (LVAD) in addition to guideline directed medical therapy (GDMT) in end stage heart failure
2016	National Institute for Health and Care Excellence (NICE)	Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel. NICE technology appraisal guidance 391
2016	Agenzia nazionale per i servizi sanitari regionali (Agenas)	Transcatheter implantable devices for mitral valve repair in adults with chronic mitral valve regurgitation
2016	National Institute for Health and Care Excellence (NICE)	Adalimumab for treating moderate to severe hidradenitis suppurativa. NICE technology appraisal guidance 392
2016	NIHR Health Technology Assessment programme	A cost-effectiveness modelling study of strategies to reduce risk of infection following primary hip replacement based on a systematic review
2016	National Institute for Health and Care Excellence (NICE)	Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. NICE technology appraisal guidance 393
2016	NIHR Health Technology Assessment programme	The feasibility of a randomised controlled trial of physiotherapy for adults with joint hypermobility syndrome
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Ceritinib (Zykadia) - non-small cell lung cancer: locally advanced or metastatic; anaplastic lymphoma kinase (ALK) positive – first line
2016	National Institute for Health and Care Excellence (NICE)	Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. NICE technology appraisal guidance 394
2016	National Institute for Health and Care Excellence (NICE)	Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer. NICE technology appraisal guidance 395
2016	NIHR Health Technology Assessment programme	Financial incentives to improve adherence to antipsychotic maintenance medication in non-adherent patients: a cluster randomised controlled trial
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Decitabine (Dacogen) - acute myeloid leukaemia: newly diagnosed de novo or secondary; adult patients of all ages who are not suitable for standard induction chemotherapy
2016	National Institute for Health and Care Excellence (NICE)	Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma. NICE technology appraisal guidance 396
2016	NIHR Health Technology Assessment programme	The Diagnosis of Urinary Tract infection in Young children (DUTY): a diagnostic prospective observational study to derive and validate a clinical algorithm for the diagnosis of urinary tract infection in children presenting to primary care with an acute illness
2016	National Institute for Health and Care Excellence (NICE)	Lumacaftorivacaftor for treating cystic fibrosis homozygous for the F508del mutation. NICE technology appraisal guidance 398
2016	NIHR Health Technology Assessment programme	CATheter Infections in CHildren (CATCH): a randomised controlled trial and economic evaluation comparing impregnated and standard central venous catheters in children
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Pembrolizumab (Keytruda) - colorectal cancer: advanced or metastatic; high-level microsatellite instability – second line
2016	National Institute for Health and Care Excellence (NICE)	Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts. NICE technology appraisal guidance 399
2016	NIHR Health Technology Assessment programme	The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer
2016	NIHR Health Technology Assessment programme	OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer
2016	NIHR Public Health Research (PHR) programme	Change in alcohol outlet density and alcohol-related harm to population health (CHALICE): a comprehensive record-linked database study in Wales
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Pembrolizumab (Keytruda) - Hodgkin lymphoma: classical; relapsed or refractory – third and fourth line
2016	National Institute for Health and Care Excellence (NICE)	Nivolumab in combination with ipilimumab for treating advanced melanoma. NICE technology appraisal guidance 400
2016	NIHR Health Technology Assessment programme	EQUATOR Network
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Quizartinib - acute myeloid leukaemia: relapsed or refractory; FLT3-internal tandem duplication (ITD) positive – second line
2016	National Institute for Health and Care Excellence (NICE)	Bosutinib for previously treated chronic myeloid leukaemia. NICE technology appraisal guidance 401
2016	NIHR Health Technology Assessment programme	Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Ribociclib with tamoxifen and goserelin, or a non-steroidal aromatase inhibitor and goserelin - breast cancer: advanced; hormone-receptor positive, human epidermal growth factor receptor 2 (HER2) negative; premenopausal women – first line
2016	National Institute for Health and Care Excellence (NICE)	Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin. NICE technology appraisal guidance 402
2016	NIHR Health Technology Assessment programme	Does therapeutic writing help people with long-term conditions? Systematic review, realist synthesis and economic considerations
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Sapacitabine - acute myeloid leukaemia: patients ≥70 years of age; not candidates for standard intensive therapy – first line
2016	National Institute for Health and Care Excellence (NICE)	Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer. NICE technology appraisal guidance 403
2016	NIHR Health Technology Assessment programme	Prediction of risk of recurrence of venous thromboembolism following treatment for a first unprovoked venous thromboembolism: systematic review, prognostic model and clinical decision rule, and economic evaluation
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Zoptarelin doxorubicin - endometrial cancer: locally advanced, recurrent or metastatic – second line
2016	National Institute for Health and Care Excellence (NICE)	Degarelix for treating advanced hormone-dependent prostate cancer. NICE technology appraisal guidance 404
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Volanesorsen - familial chylomicronemia syndrome – first line
2016	National Institute for Health and Care Excellence (NICE)	Trifluridine-tipiracil for previously treated metastatic colorectal cancer. NICE technology appraisal guidance 405
2016	NIHR Health Technology Assessment programme	A systematic review, evidence synthesis and meta-analysis of quantitative and qualitative studies evaluating the clinical effectiveness, the cost-effectiveness, safety and acceptability of interventions to prevent postnatal depression
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Simtuzumab - liver fibrosis secondary to non-alcoholic steatohepatitis or primary sclerosing cholangitis
2016	Canadian Agency for Drugs and Technologies in Health (CADTH)	Anti-vascular endothelial growth factor drugs for the treatment of retinal conditions
2016	National Institute for Health and Care Excellence (NICE)	Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 406
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Teduglutide (Revestive) - short bowel syndrome: in paediatric patients aged 1-17 years who are dependent on parenteral nutrition
2016	National Institute for Health and Care Excellence (NICE)	Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors. NICE technology appraisal guidance 407
2016	NIHR Health Technology Assessment programme	A randomised controlled trial of the probiotic Bifidobacterium breve BBG-001 in preterm babies to prevent sepsis, necrotising enterocolitis and death: the Probiotics in Preterm infantS (PiPS) trial
2016	NIHR Health Services and Delivery Research programme	Management by geographical area or management specialised by disorder? A mixed-methods evaluation of the effects of an organisational intervention on secondary mental health care for common mental disorder
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Begelomab (Begesand) - graft versus host disease: acute; steroid resistant – second line
2016	National Institute for Health and Care Excellence (NICE)	Pegaspargase for treating acute lymphoblastic leukaemia. NICE technology appraisal guidance 408
2016	NIHR Health Technology Assessment programme	An observational study to assess if automated diabetic retinopathy image assessment software can replace one or more steps of manual imaging grading and to determine their cost-effectiveness
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Caplacizumab-Thrombotic thrombocytopenic purpura: acquired; acute phase – adjunctive therapy
2016	National Institute for Health and Care Excellence (NICE)	Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion. NICE technology appraisal guidance 409
2016	NIHR Health Technology Assessment programme	BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial
2016	Agency for Healthcare Research and Quality (AHRQ)	Noninvasive testing for coronary artery disease
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Relebactam with imipenem and cilastatin - multi-drug resistant or carbapenem resistant Gram-negative infections
2016	National Institute for Health and Care Excellence (NICE)	Talimogene laherparepvec for treating unresectable metastatic melanoma. NICE technology appraisal guidance 410
2016	Agency for Healthcare Research and Quality (AHRQ)	Improving cultural competence to reduce health disparities
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Autologous haematopoietic stem cell transplantation - multiple sclerosis: relapsing remitting – second line
2016	National Institute for Health and Care Excellence (NICE)	Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer. NICE technology appraisal guidance 411
2016	Agency for Healthcare Research and Quality (AHRQ)	Early diagnosis, prevention, and treatment of Clostridium difficile: update
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Low dose desmopressin acetate (Noqdirna) - nocturia: idiopathic nocturnal polyuria; symptomatic; in adults – as sole agent or as a combination treatment
2016	National Institute for Health and Care Excellence (NICE)	Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases. NICE technology appraisal guidance 412
2016	NIHR Health Technology Assessment programme	An Occupational Therapy intervention for residents with stroke-related disabilities in UK Care Homes (OTCH): cluster randomised controlled trial with economic evaluation
2016	Agency for Healthcare Research and Quality (AHRQ)	Data linkage strategies to advance youth suicide prevention
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Dupilumab - atopic dermatitis: moderate to severe; inadequate response to treatment with topical medications or for whom topical treatments are otherwise medically inadvisable – second line
2016	National Institute for Health and Care Excellence (NICE)	Elbasvirgrazoprevir for treating chronic hepatitis C. NICE technology appraisal guidance 413
2016	NIHR Health Technology Assessment programme	Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial
2016	Agency for Healthcare Research and Quality (AHRQ)	Nonpharmacologic interventions for agitation and aggression in dementia
2016	National Institute for Health and Care Excellence (NICE)	Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma. NICE technology appraisal guidance 414
2016	Agency for Healthcare Research and Quality (AHRQ)	Treatments for fecal incontinence
2016	National Institute for Health and Care Excellence (NICE)	Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor. NICE technology appraisal guidance 415
2016	Agency for Healthcare Research and Quality (AHRQ)	Treatment strategies for patients with lower extremity chronic venous disease (LECVD)
2016	National Institute for Health and Care Excellence (NICE)	Nivolumab for previously treated advanced renal cell carcinoma. NICE technology appraisal guidance 417
2016	NIHR Health Technology Assessment programme	The HubBLe Trial: haemorrhoidal artery ligation (HAL) versus rubber band ligation (RBL) for symptomatic second- and third-degree haemorrhoids: a multicentre randomised controlled trial and health-economic evaluation
2016	Agency for Healthcare Research and Quality (AHRQ)	Retinal prostheses in the Medicare population
2016	National Institute for Health and Care Excellence (NICE)	Dapagliflozin in triple therapy for treating type 2 diabetes. NICE technology appraisal guidance 418
2016	Agency for Healthcare Research and Quality (AHRQ)	Renal denervation in the Medicare Population